Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
作者信息
Jädersten Martin
出版信息
Haematologica. 2010 Mar;95(3):348-51. doi: 10.3324/haematol.2009.019141.
Abstract
摘要
相似文献
1
Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.伴有孤立性5q缺失的骨髓增生异常综合征的病理生理学与治疗
Haematologica. 2010 Mar;95(3):348-51. doi: 10.3324/haematol.2009.019141.
2
[The 5q- syndrome].[5号染色体长臂缺失综合征]
Rev Prat. 2010 Dec 20;60(10):1420-2.
3
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Ann Hematol. 2012 Feb;91(2):309-10. doi: 10.1007/s00277-011-1263-7. Epub 2011 May 28.
4
Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.来那度胺治疗仅7天后，一名患有骨髓增生异常综合征且5号染色体长臂缺失患者的血液学和细胞遗传学反应。
Leuk Res. 2011 Sep;35(9):e175-6. doi: 10.1016/j.leukres.2011.05.020. Epub 2011 Jun 11.
5
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.来那度胺治疗伴有孤立性5号染色体长臂缺失（del(5q)）和JAK2 V617F突变的骨髓增生异常综合征患者的疗效
Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20.
6
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis.伴有孤立性5q缺失的骨髓增生异常综合征（5q-综合征）。一种以核糖体生物合成缺陷为特征的克隆性干细胞疾病。
Haematologica. 2008 Jul;93(7):967-72. doi: 10.3324/haematol.13377.
7
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.来那度胺治疗的5q缺失骨髓增生异常综合征患者的端粒缩短、克隆进化与疾病进展
Leukemia. 2012 Feb;26(2):356-8. doi: 10.1038/leu.2011.193. Epub 2011 Jul 29.
8
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.来那度胺在 del(5q) 骨髓增生异常综合征疗效中的多效作用机制。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135.
9
A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).一例伴有5号染色体长臂缺失（del(5q)）和20号染色体长臂缺失（del(20q)）的骨髓增生异常综合征患者对极短疗程来那度胺治疗的延迟但持久的反应及意外的克隆重新分布
Leuk Res. 2009 Nov;33(11):e199-202. doi: 10.1016/j.leukres.2009.06.009. Epub 2009 Jul 9.
10
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.来那度胺隔日给药对伴有5q-缺失的骨髓增生异常综合征有效。
Br J Haematol. 2010 Feb;148(3):483-4. doi: 10.1111/j.1365-2141.2009.07971.x. Epub 2009 Oct 28.
引用本文的文献
1
Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.骨髓增生异常综合征的治疗现状与新进展。
Cancer Treat Res. 2021;181:115-132. doi: 10.1007/978-3-030-78311-2_7.
2
A primary care approach to myelodysplastic syndromes.骨髓增生异常综合征的初级保健方法。
Korean J Fam Med. 2014 May;35(3):111-8. doi: 10.4082/kjfm.2014.35.3.111. Epub 2014 May 22.
3
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.来那度胺作为 del(5q) 骨髓增生异常综合征患者的疾病修饰剂：将作用机制与临床结果联系起来。
Ann Hematol. 2014 Jan;93(1):1-11. doi: 10.1007/s00277-013-1863-5. Epub 2013 Sep 10.
4
NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.低等位基因负担的NRAS突变对低风险骨髓增生异常综合征患者具有独立的预后意义。
Leukemia. 2013 Oct;27(10):2077-81. doi: 10.1038/leu.2013.160. Epub 2013 May 27.
5
Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway.5q-综合征发病机制中的重要基因及其与核糖体应激和固有免疫系统通路的联系。
Leuk Res Treatment. 2012;2012:179402. doi: 10.1155/2012/179402. Epub 2012 Feb 13.
6
L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.亮氨酸通过激活 mTOR 通路改善 Diamond-Blackfan 贫血和 del(5q) MDS 相关的贫血和发育缺陷。
Blood. 2012 Sep 13;120(11):2214-24. doi: 10.1182/blood-2011-10-382986. Epub 2012 Jun 25.
本文引用的文献
1
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.p53 依赖性机制是人类 5q-综合征小鼠模型中巨红细胞贫血的基础。
Nat Med. 2010 Jan;16(1):59-66. doi: 10.1038/nm.2063. Epub 2009 Nov 22.
2
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.鉴定 miR-145 和 miR-146a 作为 5q-综合征表型的介质。
Nat Med. 2010 Jan;16(1):49-58. doi: 10.1038/nm.2054. Epub 2009 Nov 8.
3
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.接受来那度胺治疗后未能获得持续红细胞或细胞遗传学缓解的 del(5q) MDS 患者，其克隆进化和 AML 进展的风险增加。
Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.
4
Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study.骨髓增生异常综合征 5q(del)克隆中未受损的终末红细胞分化和保持去核能力：一项单细胞研究。
Haematologica. 2010 Mar;95(3):398-405. doi: 10.3324/haematol.2009.012773. Epub 2009 Oct 8.
5
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.5q- 综合征中的克隆异质性：在来那度胺治疗期间，表达 p53 的祖细胞占优势，并在疾病进展时扩增。
Haematologica. 2009 Dec;94(12):1762-6. doi: 10.3324/haematol.2009.011528. Epub 2009 Oct 1.
6
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.来那度胺治疗对伴有 5q 染色体缺失的骨髓增生异常综合征患者造血的影响。
Haematologica. 2010 Mar;95(3):406-14. doi: 10.3324/haematol.2009.010876. Epub 2009 Sep 22.
7
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.磷酸酶单倍体不足在来那度胺对5q缺失型骨髓增生异常综合征的选择性抑制中起关键作用。
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12974-9. doi: 10.1073/pnas.0811267106. Epub 2009 May 26.
8
Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.骨髓增生异常综合征中的5号染色体长臂缺失：癌症中半合子缺失研究的范例
Leukemia. 2009 Jul;23(7):1252-6. doi: 10.1038/leu.2009.53. Epub 2009 Mar 26.
9
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.通过RNA干扰筛选鉴定RPS14为5q-综合征基因。
Nature. 2008 Jan 17;451(7176):335-9. doi: 10.1038/nature06494.
10
Targeted therapies in myelodysplastic syndrome.骨髓增生异常综合征的靶向治疗
Semin Hematol. 2008 Jan;45(1):31-8. doi: 10.1053/j.seminhematol.2007.10.001.
Zotero 插件